Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Baxter International Inc. on March 23, 2005, with the earliest event reported on the same date. The filing primarily addresses corporate governance changes and executive leadership appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Appointment: Peter S. Hellman was appointed to the Board of Directors, effective March 30, 2005. His initial term expires at the 2006 annual meeting of stockholders. Committee assignments have not yet been determined.
- Executive Appointments: Susan R. Lichtenstein was appointed Corporate Vice President, General Counsel, and Corporate Secretary.
- Business Unit Leadership: Peter J. Arduini was appointed Corporate Vice President and President of the Medication Delivery business.
- Executive Departure: David F. Drohan is retiring after 39 years with the Company, vacating the position of President of the Medication Delivery business.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No risks, contingencies, or unusual items were disclosed in this specific report. The Company stated it is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Peter S. Hellman's board term and future committee assignments.
- Confirm the transition timeline for the Medication Delivery business leadership between David F. Drohan and Peter J. Arduini.
- Review the attached press releases (Exhibits 99.1 and 99.2) for additional biographical details on the new appointees.